Diurnal Group PLC (LON:DNL)‘s stock had its “buy” rating reissued by investment analysts at Numis Securities Ltd in a note issued to investors on Monday. They currently have a GBX 187 ($2.34) price target on the stock. Numis Securities Ltd’s price target would indicate a potential upside of 66.22% from the company’s previous close.

Diurnal Group PLC (LON:DNL) opened at 112.50 on Monday. The company has a 50-day moving average of GBX 131.14 and a 200-day moving average of GBX 141.84. The company’s market cap is GBX 58.74 million. Diurnal Group PLC has a 52 week low of GBX 110.00 and a 52 week high of GBX 155.00.

Diurnal Group PLC Company Profile

Diurnal Group plc is a United Kingdom-based specialty pharmaceutical company. The Company targets patient needs in chronic endocrine (hormonal) diseases, such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. The Company has two products in late-stage clinical development targeting adrenal disease: Chronocort and Infacort.

Receive News & Stock Ratings for Diurnal Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group PLC and related stocks with our FREE daily email newsletter.